<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039351</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-20992</org_study_id>
    <secondary_id>EORTC-20992</secondary_id>
    <nct_id>NCT00039351</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      older patients who have non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete remission (CR) rate and duration of CR in frail elderly patients&#xD;
           with diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma treated with&#xD;
           cyclophosphamide, vincristine, and prednisone.&#xD;
&#xD;
        -  Determine the time to progression and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the severe toxicity rate of this regimen in these patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cyclophosphamide IV and vincristine IV on day 1 and oral prednisone on days&#xD;
      1-5. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with stage I or II non-Hodgkin's lymphoma (NHL), no baseline lactate dehydrogenase&#xD;
      (LDH) elevation, baseline WHO performance status 0-1, and longest tumor diameter of less than&#xD;
      5 cm, who achieve partial response (PR) or complete response (CR), receive 1 additional&#xD;
      course of chemotherapy. Patients then undergo involved-field radiotherapy once daily 5 days a&#xD;
      week for 3.5-4 weeks.&#xD;
&#xD;
      Patients with stage I or II NHL, a baseline LDH elevation, and/or baseline WHO performance&#xD;
      status 2-4, and/or longest tumor diameter of at least 5 cm, who achieve PR or CR, receive 3&#xD;
      additional courses of chemotherapy. Patients then undergo involved-field radiotherapy once&#xD;
      daily 5 days a week for 3.5-4 weeks.&#xD;
&#xD;
      Patients with stage III or IV NHL who achieve CR or PR receive 3 additional courses of&#xD;
      chemotherapy. Patients then undergo consolidative radiotherapy once daily 5 days a week for&#xD;
      2.5-3 weeks.&#xD;
&#xD;
      Quality of life is assessed at baseline, after the third chemotherapy course, at the end of&#xD;
      chemotherapy, every 6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      Patients are followed every 3 months for 3 years, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 29-56 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">32</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of diffuse large B-cell or peripheral T-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  No Burkitt's-like lymphoma&#xD;
&#xD;
               -  Small cells in bone marrow allowed&#xD;
&#xD;
          -  Previously untreated NHL&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 1.1 cm&#xD;
&#xD;
          -  Poor physiological status with at least 1 of the following:&#xD;
&#xD;
               -  WHO performance status of 3-4&#xD;
&#xD;
               -  LVEF less than 50%&#xD;
&#xD;
               -  Creatinine clearance less than 50 mL/min&#xD;
&#xD;
               -  Neutrophil count no greater than 1,500/mm^3&#xD;
&#xD;
               -  Platelet count no greater than 100,000/mm^3&#xD;
&#xD;
               -  Concurrent severe disease that would preclude cyclophosphamide, vincristine,&#xD;
                  prednisolone, and doxorubicin&#xD;
&#xD;
          -  No cerebral or meningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  70 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell skin&#xD;
             cancer, curatively treated carcinoma in situ of the cervix, or curatively treated&#xD;
             solid tumor&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Soubeyran, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergoni√©</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Network Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>B 1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Egypt</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre D'Oncologie Du Pays-Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>F-64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra (HUC)</name>
      <address>
        <city>Coimbra</city>
        <zip>3001-301</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Thonex-Geneve</city>
        <zip>CH-1226</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>England</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dumfries Royal Infirmary</name>
      <address>
        <city>Dumfries</city>
        <zip>DG1 4AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

